Brookmont Capital Management Acquires 7,322 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Brookmont Capital Management grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,083 shares of the biopharmaceutical company's stock after purchasing an additional 7,322 shares during the quarter. Gilead Sciences comprises approximately 2.5% of Brookmont Capital Management's portfolio, making the stock its 8th largest holding. Brookmont Capital Management's holdings in Gilead Sciences were worth $4,719,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. AE Wealth Management LLC grew its stake in shares of Gilead Sciences by 11.7% in the 2nd quarter. AE Wealth Management LLC now owns 29,796 shares of the biopharmaceutical company's stock valued at $2,044,000 after buying an additional 3,124 shares during the period. Fidelis Capital Partners LLC grew its position in Gilead Sciences by 39.7% in the second quarter. Fidelis Capital Partners LLC now owns 4,226 shares of the biopharmaceutical company's stock worth $313,000 after acquiring an additional 1,201 shares during the period. Itau Unibanco Holding S.A. increased its stake in Gilead Sciences by 140.1% during the second quarter. Itau Unibanco Holding S.A. now owns 3,705 shares of the biopharmaceutical company's stock worth $254,000 after acquiring an additional 2,162 shares during the last quarter. Harmony Asset Management LLC purchased a new stake in Gilead Sciences in the second quarter valued at $262,000. Finally, Steel Grove Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 4.1% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 25,390 shares of the biopharmaceutical company's stock valued at $1,742,000 after purchasing an additional 1,002 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $1.12 during mid-day trading on Tuesday, reaching $92.96. The stock had a trading volume of 10,544,871 shares, compared to its average volume of 7,055,390. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The business has a 50 day simple moving average of $91.65 and a 200 day simple moving average of $84.38. The firm has a market capitalization of $115.85 billion, a price-to-earnings ratio of 1,032.89, a PEG ratio of 1.29 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.29 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences's dividend payout ratio is currently 3,422.22%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. UBS Group increased their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an "outperform" rating and a $110.00 target price on the stock. Oppenheimer lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.